DSM Biologics to Acquire Rhobust Technology from Upfront Chromatography

DSM Biologics, a business unit of DSM Pharmaceutical products, said it has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Danish Upfront Chromatography for pharmaceutical and other applications.

As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the Rhobust technology in various fields, including the pharma industry. The Rhobust technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies. DSM Biologics will continue to support all existing clients for this technology.

The parties have agreed to not disclose financial details.

Company

DSM Pharmaceutical Products

45 Waterview Blvd.
Parsippany, NJ 07054-1298

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.